The EBV EliSpot (latent) assesses T-cell responses to EBV latent-phase antigens and reports a Stimulation Index (SI) (0–1 negative, 2–3 weak positive, >3 positive). Because it captures cellular immunity, it’s best interpreted with EBV serology (VCA-IgM/IgG, EBNA-1 IgG, EA-IgG) and, when clinically relevant, EBV DNA PCR to evaluate replication. A positive result (>3 SI) reflects a clear immune response to latent EBV, which can support recent or ongoing immune engagement with EBV when symptoms fit, but it does not quantify viral load or diagnose disease on its own. Consider correlating with symptoms and basic labs, and trend over 4–6 weeks if uncertainty remains. Results may be affected by immunosuppression and pre-analytical handling; always use the performing lab’s cutoffs.
The EBV EliSpot (lytic) by ArminLabs measures T-cell (IFN-γ) responses to EBV lytic-phase antigens, reported as a Stimulation Index (SI) that compares reactivity to a control. Reference ranges: 0–1 SI negative, 2–3 SI weak positive, >3 SI positive. A higher SI indicates more EBV-reactive T cells and, when paired with compatible symptoms, can support recent infection or reactivation; however, strong responses may also reflect immune memory, so results must be interpreted in clinical context. Use this test alongside EBV serology (VCA-IgM/IgG, EBNA-1 IgG, EA-IgG) to help stage infection and EBV DNA PCR to assess active replication/viral load; consider CBC and liver enzymes if symptomatic. For equivocal cases or to assess dynamics, repeat in 4–6 weeks and look for trends. Results can be influenced by immunosuppression, intercurrent illness, and pre-analytical handling. This assay does not diagnose EBV disease or quantify virus on its own; rely on the total picture—symptoms, exam, serology, PCR, and routine labs—for decisions.
helps diagnosing and understanding an Epstein-Barr Virus (EBV) infection
Epstein-Barr virus nuclear antigen antibody in serum
Epstein-Barr virus DNA measured in whole blood.
quantitative detection of Epstein-Barr virus DNA
Epstein-Barr virus capsid antibody, IgG class, in blood.
The Epstein-Barr Virus Viral Capsid Antigen IgM (EBV VCA IgM) test is a vital part of the Epstein-Barr Virus VCA Antibody Panel, a key diagnostic tool for identifying EBV infections. EBV, a common virus known for causing infectious mononucleosis, also has links to certain cancers and autoimmune disorders. The EBV VCA IgM test specifically measures the IgM antibodies that the immune system produces in response to the viral capsid antigen of EBV, which are among the first antibodies to appear following an infection with the virus. These antibodies typically signify an acute or recent EBV infection. The presence of EBV VCA IgM antibodies is an essential marker for healthcare professionals in diagnosing active EBV infections. Elevated levels of these antibodies usually indicate that the infection is in its early stages, often before more severe symptoms develop. This early detection is crucial for prompt and effective patient management, especially in cases where symptoms might be confused with other illnesses. Moreover, the EBV VCA IgM test is particularly valuable in differentiating between acute and past EBV infections. Since IgM antibodies are produced early in the infection and typically decline as the infection resolves, their presence points to a recent exposure to the virus. In contrast, the absence of EBV VCA IgM, coupled with the presence of other EBV antibodies (like VCA IgG or EBNA IgG), often suggests a past infection or a reactivation of a latent infection. Given the widespread prevalence of EBV, the EBV VCA IgM test, as a part of the comprehensive Epstein-Barr Virus VCA Ab Panel, becomes a significant tool in diagnosing and understanding the timeline of an EBV infection. This test is particularly relevant for individuals presenting with symptoms like fever, sore throat, and swollen lymph nodes, which are characteristic of mononucleosis but can also overlap with other conditions. Accurate diagnosis through the EBV VCA IgM test thus plays a critical role in guiding appropriate treatment strategies and informing patients about the nature and stage of their infection. In the broader healthcare context, this test contributes significantly to managing and monitoring EBV-related health issues, making it a cornerstone of infectious disease diagnostics.
an antibody related to Epstein-Barr virus
The marker ECP on a LabCorp panel refers to Eosinophil Cationic Protein, a protein released by activated eosinophils—white blood cells involved in the body's immune response, particularly in allergic reactions and parasitic infections. ECP plays roles in immune regulation and has cytotoxic and neurotoxic properties. Clinical Significance Measuring ECP levels in the blood can provide insights into eosinophil activity and is useful in evaluating and monitoring various conditions, including: Asthma: Elevated ECP levels can reflect the degree of eosinophilic inflammation in the airways, aiding in assessing asthma severity and guiding corticosteroid therapy. Allergic Conditions: In diseases like allergic rhinitis and atopic dermatitis, increased ECP levels correlate with symptom severity, making it a valuable marker for disease activity. Eosinophilic Gastrointestinal Disorders: Conditions such as eosinophilic esophagitis, gastroenteritis, and colitis may show elevated ECP levels, reflecting eosinophil-mediated inflammation. Parasitic Infections: ECP levels can rise in response to certain parasitic infestations, indicating an active eosinophilic response. Hypereosinophilic Syndromes: In disorders characterized by persistently high eosinophil counts, ECP measurement can help assess disease activity and organ involvement.
Kidney Health
Estimates how well your kidneys filter waste from blood.
The eGFR (estimated Glomerular Filtration Rate) / Cystatin C Ratio is a significant marker offering vital insights into kidney function and health. Glomerular filtration rate (GFR) is a test that measures the flow rate of filtered fluid through the kidneys, serving as a critical indicator of kidney health. eGFR is an estimated value derived from blood creatinine levels, age, sex, and race, providing a non-invasive assessment of kidney function. Cystatin C, on the other hand, is a protein produced by all nucleated cells in the body, and its level in the blood inversely correlates with kidney function. Unlike creatinine, Cystatin C levels are less influenced by muscle mass, age, or diet, making it a potentially more accurate marker of kidney function for certain populations. By evaluating the eGFR/Cystatin C ratio, healthcare providers can gain a more nuanced understanding of kidney function. This ratio can be particularly useful in cases where creatinine-based eGFR might be less reliable, such as in elderly patients, those with significant muscle mass changes, or in people with a vegetarian diet. A higher ratio may indicate better kidney function, while a lower ratio could suggest impaired kidney health. This marker, part of the comprehensive Kidney Test panel from Boston Heart Diagnostics, helps in diagnosing and managing kidney diseases more effectively, enabling personalized treatment strategies to maintain or improve kidney health.
Associated With: Loss of oral tolerance
Egg white IgG reactivity marker